A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Clinical trial NCT05829226 · COMPLETED

Trial details

NCT number: NCT05829226
Sponsor: PureTech
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

AML, Adult Recurrent MDS

Start date: 2022-12-12
Primary completion: 2025-12-31
Enrollment: 101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.